drug

Big Pharma to start charging $1 million per patient for gene therapy drugs

Sunday, January 13, 2013 by: Ethan A. Huff, staff writer
Tags: Big Pharma, gene therapy, drugs

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
The five biggest lies about Ebola being pushed by government and mass media
White House admits staging fake vaccination operation to gather DNA from the public
Why does the CDC own a patent on Ebola 'invention?'
Ultraviolet light robot kills Ebola in two minutes; why doesn't every hospital have one of these?
EXCLUSIVE: Natural News tests flu vaccine for heavy metals, finds 25,000 times higher mercury level than EPA limit for water
Irrefutable proof we are all being sprayed with poison: 571 tons of toxic lead 'chemtrailed' into America's skies every year
Truvia sweetener a powerful pesticide; scientists shocked as fruit flies die in less than a week from eating GMO-derived erythritol
Russia taking McDonald's to court, threatens countrywide shutdown
Oregon man serving prison sentence for collecting rainwater on his own property
Senator who attacked Doctor Oz over dietary supplements received over $146,000 in campaign contributions from Big Pharma mega-retailer and Monsanto
Global warming data FAKED by government to fit climate change fictions
Healthy 12-year-old girl dies shortly after receiving HPV vaccine
HOAX confirmed: Michelle Obama 'GMOs for children' campaign a parody of modern agricultural politics
Ebola outbreak may already be uncontrollable; Monsanto invests in Ebola treatment drug company as pandemic spreads
Ben & Jerry's switches to non-GMO, Fair Trade ice cream ingredients
W.H.O. contradicts CDC, admits Ebola can spread via coughing, sneezing and by touching contaminated surfaces
Elliot Rodger, like nearly all young killers, was taking psychiatric drugs (Xanax)
BREAKING: CDC whistleblower confesses to MMR vaccine research fraud in historic public statement
Delicious
(NaturalNews) Greedily clawing for new ways to generate as much profit as logistically possible, the pharmaceutical industry has taken a renewed interest in developing novel drugs for so-called "orphan" diseases, or extremely rare health conditions that affect only a miniscule percentage of the overall population. Though the market for such drugs is small, it is currently the fastest growing segment of the drug industry because drug manufacturers are getting away with charging upwards of $1 million or more per patient who receives such treatments, and nobody is doing anything to stop them.

If you thought the costs associated with mass-produced patented drugs was high, consider the fact that patients with the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH), for instance, are typically billed a whopping $440,000 per year to be treated with the Alexion Pharmaceuticals drug Soliris (eculizumab). And patients with a rare form of the lung disease cystic fibrosis are currently being charged upwards of $300,000 for treatment with the Vertex Pharmaceuticals drug Kalydeco (ivacaftor).

Where prices really get crazy, though, is with a new drug called Glybera (alipogene tiparvovec), which was recently approved in Europe for the treatment of lipoprotein lipase deficiency (LPLD). According to Reuters, the drug, which is manufactured by the Dutch company UniQure, will cost more than $1 million per patient when it hits the market this summer, and will be among the most expensive drugs currently available to patients. And the only reason it will cost so much is that UniQure can charge as much as it wants for the drug without penalty, as there are no government-approved alternatives.

Big Pharma capitalizing on rare conditions for obscene profits

It is all part of a crafty new scheme by Big Pharma to take advantage of individuals with rare health conditions, whose insurance companies can be billed obscene amounts of money for specialized treatments unavailable anywhere else. Since drug companies are having an increasingly hard time coming up with new drugs for the mass disease market, they are turning to more uncommon conditions with the hope they can both rush new drugs to market, and generate huge profits on their limited sale.

"More companies are getting into this sector because they've seen the eye-wateringly high prices that can be charged for some of these very rare disease medicines," explained Karl Claxton, professor of health economics at the University of York in the U.K., about Big Pharma's scandalous greed. "It's unsustainable. Healthcare systems around the world are under increasing financial pressure and all of them are starting to look very carefully at what they get for their money."

But at this point in time, many health insurance providers continue to cover these novel treatments, as there are often no other government-approved options. You can think of it as a type of state-sanctioned monopoly on medicine that preys on those with the most atypical and hardest to treat conditions. And beyond this, the drug industry is actually pushing to have novel orphan drugs rushed to market without proper safety trials, further exploiting the "urgent" needs of patients with rare health conditions.

So far in 2012, the U.S. Food and Drug Administration (FDA) has approved at least four new orphan drugs to treat rare conditions, including drugs for the blood and bone marrow disease myelogenous leukemia, Gaucher disease, Hodgkin lymphoma, anaplastic large cell lymphoma, and cystic fibrosis. It is expected that each of these drugs will cost several hundreds of thousands of dollars or more per year, further illustrating the runaway costs associated with conventional medicine.

Sources for this article include:

http://www.reuters.com

http://www.fiercebiotech.com

http://www.fool.com

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.